Associations - EGFR wild-type

EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: B - Late Trials	durvalumab Sensitive: B - Late Trials
EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	rivoceranib Sensitive: C2 – Inclusion Criteria	rivoceranib Sensitive: C2 – Inclusion Criteria
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	rivoceranib Sensitive: C2 – Inclusion Criteria	rivoceranib Sensitive: C2 – Inclusion Criteria
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria	erlotinib Sensitive: C2 – Inclusion Criteria
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: C2 – Inclusion Criteria	atezolizumab Sensitive: C2 – Inclusion Criteria
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: C2 – Inclusion Criteria	nivolumab Sensitive: C2 – Inclusion Criteria
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: C3 – Early Trials	pemetrexed Sensitive: C3 – Early Trials
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	cabozantinib tablet Sensitive: C3 – Early Trials	cabozantinib tablet Sensitive: C3 – Early Trials
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	erlotinib + cabozantinib tablet Sensitive: C3 – Early Trials	erlotinib + cabozantinib tablet Sensitive: C3 – Early Trials
EGFR wild-type EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	tislelizumab Sensitive: C3 – Early Trials	tislelizumab Sensitive: C3 – Early Trials
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	REC-4881 Sensitive: D – Preclinical	REC-4881 Sensitive: D – Preclinical
EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	AZD8330 Sensitive: D – Preclinical	AZD8330 Sensitive: D – Preclinical
EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	PF-04691502 Sensitive: D – Preclinical	PF-04691502 Sensitive: D – Preclinical
EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	GSK2126458 Sensitive: D – Preclinical	GSK2126458 Sensitive: D – Preclinical
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	RTB101 Sensitive: D – Preclinical	RTB101 Sensitive: D – Preclinical
EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	EGFR wild-type EGFR wild-type	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: D – Preclinical	gefitinib Sensitive: D – Preclinical